- Home
- JF vs NCEL Comparison
JF vs NCEL Comparison
Compare JF & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JF | NCEL |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | China | Switzerland |
| Employees | N/A | 11 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 13.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JF | NCEL |
|---|---|---|
| Price | $0.92 | $2.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.1K | ★ 15.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.89 | $1.89 |
| 52 Week High | $1.12 | $4.70 |
Technical Indicators
Market Signals| Indicator | JF | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 42.89 | 48.64 |
| Support Level | $0.89 | $2.63 |
| Resistance Level | $1.00 | $3.19 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 5.67 | 24.44 |
Price Performance
Historical ComparisonAbout JF J and Friends Holdings Limited American Depositary Shares
J and Friends Holdings Ltd, formerly Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees, as well as by providing financing for these borrowers and earning installment service fees. The company earns wealth management services fees and commissions on financial products. The company generates the majority of its revenue from Wealth management service fees and others.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.